Compare BLDR & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | RDY |
|---|---|---|
| Founded | 1998 | 1984 |
| Country | United States | India |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.6B |
| IPO Year | 2005 | 2001 |
| Metric | BLDR | RDY |
|---|---|---|
| Price | $84.88 | $13.74 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $133.00 | $16.90 |
| AVG Volume (30 Days) | ★ 2.3M | 1.9M |
| Earning Date | 04-30-2026 | 05-08-2026 |
| Dividend Yield | N/A | ★ 0.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.89 | N/A |
| Revenue | ★ $15,190,638,000.00 | N/A |
| Revenue This Year | $1.00 | $7.50 |
| Revenue Next Year | $4.52 | $2.96 |
| P/E Ratio | $20.74 | ★ $18.67 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $80.00 | $12.26 |
| 52 Week High | $151.03 | $16.17 |
| Indicator | BLDR | RDY |
|---|---|---|
| Relative Strength Index (RSI) | 34.04 | 39.73 |
| Support Level | N/A | $13.23 |
| Resistance Level | $130.47 | $14.14 |
| Average True Range (ATR) | 3.61 | 0.23 |
| MACD | -0.42 | -0.09 |
| Stochastic Oscillator | 25.84 | 14.36 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.